Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

20.05USD
28 Mar 2017
Change (% chg)

$-0.15 (-0.74%)
Prev Close
$20.20
Open
$20.20
Day's High
$20.45
Day's Low
$19.80
Volume
33,481
Avg. Vol
49,820
52-wk High
$24.30
52-wk Low
$12.35

Latest Key Developments (Source: Significant Developments)

Revance completes enrollment in phase 3 pivotal trials of RT002 Injectable
Tuesday, 7 Mar 2017 08:10am EST 

Revance Therapeutics Inc : Revance completes enrollment in phase 3 pivotal trials of RT002 Injectable for the treatment of glabellar (frown) lines .Revance Therapeutics Inc - company expects to report topline results from both pivotal phase 3 trials in Q4 of 2017..  Full Article

Revance Therapeutics Inc says superior court for county of Santa Clara issued an order
Thursday, 12 Jan 2017 06:30am EST 

Revance Therapeutics Inc : Revance Therapeutics Inc- on Jan 6, superior court for county of santa clara issued an order preliminarily approving class action settlement . Revance Therapeutics - has agreed to settle litigation for $6.4 million in cash, of which co expects $5.9 million to be covered by its insurance policies .Revance Therapeutics Inc- it is anticipated that settlement, if approved, would not have a material impact on company's business.  Full Article

Revance releases third quarter 2016 results
Thursday, 3 Nov 2016 04:05pm EDT 

Revance Therapeutics Inc - : Qtrly loss per share $0.64 . Expects its 2016 GAAP operating expense to now be in range of $84 to $96 million .Revance releases third quarter 2016 results.  Full Article

Revance expects FY cash burn in range of $90 to $100 mln
Thursday, 4 Aug 2016 04:05pm EDT 

Revance Therapeutics Inc : Revance releases second quarter 2016 results . Expects its cash burn for 2016 to be in range of $90 to $100 million .Qtrly loss per share $0.88.  Full Article

Revance Therapeutics plans to initiate global phase 3 program in second half of 2016
Thursday, 14 Jul 2016 04:02pm EDT 

Revance Therapeutics Inc : Revance Announces Completion Of Pre-Phase 3 meeting with FDA for rt002 injectable to treat glabellar lines . Company plans to initiate global phase 3 program in second half of 2016 .Co's phase 3 program will include two placebo-controlled pivotal studies conducted at multiple sites in US and Canada.  Full Article

Revance reports results for RT001 topical Phase 3 trial for lateral canthal lines
Monday, 13 Jun 2016 04:01pm EDT 

Revance Therapeutics Inc : Revance reports results for RT001 topical Phase 3 trial for lateral canthal lines . RT001 topical generally appeared to be well-tolerated in study . In realise 1, daxibotulinumtoxina topical gel (RT001) did not achieve its co-primary and other endpoints . Do not plan to continue development of RT001 topical for crow's feet . Based on results, have decided not to pursue current clinical development plan for RT001 in axillary hyperhidrosis .Now expect its cash and investments to fund its operations into Q2 of 2018.  Full Article

Revance releases Q1 2016 results
Monday, 9 May 2016 04:05pm EDT 

Revance Therapeutics Inc : Reaffirms its 2016 full year guidance . Net loss for q1 ended march 31, 2016 was $19.9 million .Revance releases first quarter 2016 results.  Full Article

Revance Therapeutics, Inc reports positive 6-month duration in BELMONT Study
Thursday, 29 Oct 2015 07:00am EDT 

Revance Therapeutics, Inc:Says announced positive 24-week results today from its multi-center Belmont phase 2 active comparator study of injectable rt002.6-month duration of effect in Belmont study is statistically significant compared to botox cosmetic.Says all dose levels of rt002 achieved statistically significant, investigator-reported efficacy compared to placebo at week 4.Says all dose levels of rt002 appear to be safe and well tolerated.  Full Article

Revance Therapeutics Initiates Phase 2 Clinical Study of Its Unique Botulinum Toxin Type A
Tuesday, 29 Sep 2015 04:00pm EDT 

Revance Therapeutics:Says initiation of patient dosing in a Phase 2 dose-escalating clinical study of RT002 investigational drug product candidate to treat cervical dystonia, a neurological muscle movement disorder.Phase 2 study will evaluate safety, preliminary efficacy, and duration of effect of RT002 for injection in patients with moderate-to-severe isolated cervical dystonia symptoms of the neck\.  Full Article

Revance Therapeutics, Inc initiates phase 2 clinical trial of Botulinum Toxin Type A Topical Gel
Wednesday, 9 Sep 2015 04:02pm EDT 

Revance Therapeutics, Inc:Initiates phase 2 clinical trial of botulinum toxin type a topical gel to treat axillary hyperhidrosis.Says expects to enroll a total of approximately 60 adult patients at multiple sites in the United States.Says company plans to release interim data from the study by year end 2015.  Full Article

More From Around the Web

BRIEF-Revance completes enrollment in phase 3 pivotal trials of RT002 Injectable

* Revance completes enrollment in phase 3 pivotal trials of RT002 Injectable for the treatment of glabellar (frown) lines